EllieMD Semaglutide Review

EllieMD sells compounded GLP-1 preparations through a telehealth intake, with a 503A pharmacy partner and a menu of additive blends. Our research (August 8, 2026) found a marketing claim that cannot be reconciled with the clinical literature, or with EllieMD's own published guidance.

The 26% Claim

EllieMD's site states, verbatim:

"EllieMD offers a powerful, pharmacologically-backed approach to metabolic health and sustainable weight management. Scientific rigor translates into profound benefits for patients, with data indicating the potential to lose up to 26%+ of initial body weight over 6-8 weeks."

A banner elsewhere on the site reads "LOSE UP TO 26%* BODY WEIGHT." No trial of any GLP-1 medication supports this. The highest weight reduction produced by any agent in this class in a published randomised trial is SURMOUNT-1, where tirzepatide 15 mg produced a mean reduction of about 20.9% — over 72 weeks. STEP 1 produced roughly 14.9% with semaglutide 2.4 mg over 68 weeks. EllieMD's claim compresses a 72-week result into 6–8 weeks and then exceeds it. EllieMD's own FAQ contradicts the banner. Elsewhere on the same site, the company states that "a safe and steady rate of loss is typically 1–2 pounds per week (6–8 pounds per month)." For a 200-pound patient, eight weeks at that rate is 8–16 pounds — 4% to 8% of body weight. The 26% headline would require losing 52 pounds in eight weeks, roughly 6.5 pounds per week, more than three times the rate the company itself calls safe. Both statements are on EllieMD's website. They cannot both be true.

The Products Are Never Named

EllieMD markets by mechanism rather than by drug. Its menu lists "GLP-1 Injection," "GLP-1/GIP Injection," "GLP-1 Oral Drops," "GLP-1/GIP Oral Drops," "GLP-1 + NAD Oral Drops," and versions blended with L-carnitine, glycine or B12. The words semaglutide and tirzepatide do not appear in this product naming. A patient reading the menu cannot tell from it which molecule they are being prescribed, at what dose, or what evidence applies. The company does state that formulations are prepared by a 503A pharmacy it calls Clover.

Eligibility Runs Below Every Approved Threshold

EllieMD publishes a three-tier BMI floor: 25+ for new patients, 22+ for transfers from another program within 45 days, and 20+ for microdose injections. For context, Wegovy and Zepbound are FDA-approved at BMI 30+, or 27+ with a weight-related condition. A BMI of 20 is squarely within the normal range. As our eligibility guide explains, prescribing an appetite-suppressing medication to someone at a healthy weight is a different proposition from treating obesity, and it is worth understanding why a program's floor sits where it does.

What EllieMD Does Publish

In fairness: intake is reviewed by a state-licensed MD, DO or qualified provider; there are no separate membership, shipping or consultation fees; nausea medication and lab work are included in the starter kit; and the company gives specific, checkable storage guidance (stable at room temperature up to 86°F for up to 56 days, refrigeration recommended). It discloses standard contraindications, including medullary thyroid carcinoma and MEN 2. It also states that each batch is tested for purity, potency and sterility before shipping. Those are reasonable practices. They do not offset a headline weight-loss figure the company's own safety guidance contradicts.